Bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
As with cocaine in Coca-Cola, lithium was widely marketed as one of several patent medicine products popular in the late 19th and early 20th centuries and was claimed to be included in many drinks including lithia water and 7 Up. Charles Leiper Grigg, who launched his St. Louis-based company The Howdy Corporation, invented a formula for a lemon-lime soft drink in 1920. The product, at one point named "7Up Lithiated Lemon Soda", was launched two weeks before the Wall Street Crash of 1929. It claimed to contain the mood stabilizer lithium citrate, and was one of many patent medicine products popular in the late-19th and early-20th centuries. All references to lithium were removed in 1937 after it became clear that 7Up contains no lithium. Many sources written by scientists (instead of historians) incorrectly report that 7 Up was forced to remove lithium in 1948, with an FDA action that supposedly banned lithium from beverages. Despite the supposed ban, in 1950, the Painesville Telegraph still carried an advertisement for a lithiated lemon beverage.
In August 2004, Palatin signed an agreement with King Pharmaceuticals to co-develop bremelanotide in the US and jointly license it outside the US; King paid Palatin $20 million upfront. Palatin conducted Phase II trials of intranasal bremelanotide in both female sexual dysfunction (FSD) and male erectile dysfunction (ED), but these trials were halted by the FDA in 2007, due to increased blood pressure in clinical trial subjects; Palatin stopped development of the intranasal formulation in 2008. Four trials were conducted in ED, the last being a Phase IIb published in 2008. King terminated the co-development agreement shortly after the FDA halted the trials. The drug was then reformulated to be delivered by injection and trials continued in FSD. A phase II dose-finding trial in FSD in which the drug was administered 45 minutes before sex showed promise at the highest dose and only transient signs of high blood pressure; two Phase III trials were launched at the end of 2014. Palatin launched the Phase III trials with bremelanotide administered via an autoinjector. In 2014, Palatin licensed European rights to bremelanotide to Gedeon Richter Plc. for around $10 million, and Palatin received a milestone payment of around $3 million when it started the Phase III trials in the US. In September 2016, Palatin and Gedeon Richter terminated that agreement. In November 2016, Palatin announced results of the Phase III trials, and shortly thereafter began seeking a partner to complete development in the US.
== Prognosis == The prognosis for individuals with severe LNS is poor. Death is usually due to kidney failure or complications from hypotonia, in the first or second decade of life. Less severe forms have better prognosis.
Sources: en.wikipedia.org
== Further reading == Ellington, W Ross (2001). "Evolution and Physiological Roles of Phosphagen Systems". Annual Review of Physiology. 63 (1): 289–325. doi:10.1146/annurev.physiol.63.1.289. PMID 11181958. Eggleton, Philip; Eggleton, Grace Palmer (1927). "The physiological significance of "phosphagen"". Journal of Physiology. 63 (2): 155–161. doi:10.1113/jphysiol.1927.sp002391. PMC 1514923. PMID 16993876. Eggleton, Philip; Eggleton, Grace Palmer (1928). "Further observations on phosphagen". Journal of Physiology. 65 (1): 15–24. doi:10.1113/jphysiol.1928.sp002457. PMC 1515019. PMID 16993934. Baldwin, Ernest (1933). "PHOSPHAGEN". Biological Reviews. 8 (1): 74–105. doi:10.1111/j.1469-185X.1933.tb01088.x. ISSN 1464-7931. S2CID 221532329.
== Prevalence == In the United States, approximately 40,000 people were lobotomized, and in England, 17,000 lobotomies were performed. According to one estimate, in the three Nordic countries of Denmark, Norway, and Sweden, a combined figure of approximately 9,300 lobotomies was performed. Scandinavian hospitals lobotomized 2.5 times as many people per capita as hospitals in the US. According to another estimate, Sweden lobotomized at least 4,500 people between 1944 and 1966, mainly women. This figure includes young children. And in Norway, there were 2,005 known lobotomies. In Denmark, there were 4,500 known lobotomies. The Soviet Union banned the practice in 1950 on moral grounds. In Germany, it was performed only a few times. By the late 1970s, the practice of lobotomy had generally ceased, although it continued as late as the 1980s in France. As of 2019, legality of the procedure in the United States varies according to state law, with some states restricting it heavily, while others effectively leave its regulation to laws of general applicability.
About 20,000 protein-coding genes are expressed in human cells and almost 75% of these genes are expressed in the normal prostate. About 150 of these genes are more specifically expressed in the prostate, with about 20 genes being highly prostate specific. The corresponding specific proteins are expressed in the glandular and secretory cells of the prostatic gland and have functions that are important for the characteristics of semen, including prostate-specific proteins, such as the prostate specific antigen (PSA), and the prostatic acid phosphatase.
The World Health Organization stresses that the disease is a societal responsibility and that these dietary choices should be made the most available, affordable, and accessible options. Medications can be used, along with a suitable diet, to reduce appetite or decrease fat absorption. If diet, exercise, and medication are not effective, a gastric balloon or surgery may be performed to reduce stomach volume or length of the intestines, leading to earlier satiety, or a reduced ability to absorb nutrients from food. Metabolic surgery promotes weight loss not only by reducing caloric intake but also by inducing sustained changes in the secretion of gut hormones involved in appetite and metabolic regulation. Obesity is a leading preventable cause of death worldwide, with increasing rates in adults and children. In 2022, over 1 billion people lived with obesity worldwide (879 million adults and 159 million children), representing more than double the adult cases (and four times higher than cases among children) registered in 1990. 12.1% of the worlds adult population was obese in 2012 to 16.2% in 2024, with projections of 18.6% by 2030. Obesity is more common in women than in men. Obesity is often stigmatized in many parts of the world. Conversely, some cultures, past and present, have a favorable view of obesity, seeing it as a symbol of wealth and fertility. The World Health Organization, the US, Canada, Japan, Portugal, Germany, the European Parliament and medical societies (such as the American Medical Association) classify obesity as a disease.
Sources: en.wikipedia.org
The first entry of venous blood is from the convergence of two or more capillaries into a microscopic, post-capillary venule. Post-capillary venules have a diameter of between 10 and 30 micrometres (μm), and are part of the microcirculation. Their endothelium is made up of flattened oval or polygon shaped cells surrounded by a basal lamina. Post-capillary venules are too small to have a smooth muscle layer and are instead supported by pericytes that wrap around them. Post-capillary venules become muscular venules when they reach a diameter of 50 μm, and can reach a diameter of 1 mm. These larger venules feed into small veins.
=== Varieties and cultivars === Lotus varieties have been classified according to their use into three types: rhizome lotus, seed lotus, and flower lotus. Varieties that show more than one of these characteristics are classified by the strongest feature. Regarding production area in China, rhizome lotus has the largest area with 200,000 ha (490,000 acres), followed by seed lotus with 20,000 ha (49,000 acres).
TIG1 is a transmembrane protein which contains a hyaluronic acid binding motif. This particular motif suggests that it may increase cell-to-cell contact in cells which express TIG1 (Jing et al., 2002). TIG1 is predicted to contain a membrane anchor at the N-terminus. TIG1 contains two faces: the first face contains homology to the protein latexin, and the second contains a broad basic patch. The basic face is thought to be an interaction surface. Supporting the idea of a protein interaction surface, TIG1 also contains a cis-peptide bond between isoleucine-122 and proline-123 on a protruding loop that lies on its basic face (Aagard et al., 2005). Latexin and TIG1 have approximately 30 percent homology based on primary structure; however, their three-dimensional structures are thought to be much more similar (Liang et al., 2007). Both latexin and TIG1 are thought to have descended from a common progenitor. TIG1 also shares homology with another protein, ovacalyxin-32, although the evolutionary and functional relationship between the two proteins is unclear (Gautron et al., 2001).
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.